| |

Interview with Matt Stang, CEO of Delic Corp

ByPsychedelic Spotlight

Similar Posts

  • Interview With Payton Nyquvest

    Listen, Podcasts

    In this episode of the Psychedelic Spotlight podcast, Global Trac Solutions, Inc. CEO, David Flores, sits down with Payton Nyquvest, CEO and Chairman of Numinus Wellness, Inc.

  • HUGE News on Compass Pathways (CMPS) Patents [ + Updates on MINDMED (MMED/MMEDF) ENBI, CYBN & MYCOF]

    Listen, Videos

    In today’s episode of “This Week in Psychedelic Stocks”, we have News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Cybin (CYBN) & Mydecine (MYCO / MYCOF).

    I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the FTSE so that MMED / MMEDF news is not in this episode. However, this wasn’t the only big news this week. Compass Pathways (CMPS) received not one but 2 new patents and surely, some of you might find this news worth discussing…

    We will cover the latest developments in the field writ large.
    This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

    Timestamps:
    0:00 – Intro
    0:55 – Psilocybin to treat OCD?
    5:28 – The Psychedelic Industry worth $300 Billion by 2027?
    8:24 – MindMed stock news ( MMED / MMEDF / MMQ)
    11:39 – Compass Pathways stock news ( CMPS)
    15:07 – Entheon Biomedical Corp stock news ( ENBI / ENTBF )
    19:25 – Cybin stock news ( CYBN / CLXPF )
    22:52 – Mydecine stock new ( MYCO / MYCOF )

    So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#CompassPathways​​ #Entheon

  • Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences

    Interviews, Listen, Podcasts

    In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain. 

  • Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward

    Listen, Videos

    When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.

    To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight
    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.

    In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
    The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
    There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.

    Links:
    Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
    https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/

    MAPS Phase 3 MDMD for PTSD Trial
    https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/

    Compass Pathways Phase 2b Psilocybin for Depression Trial
    https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #PsychedelicStocks #MindMed #Cybin